Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
25
08
2019
accepted:
16
11
2019
entrez:
7
3
2020
pubmed:
7
3
2020
medline:
7
3
2020
Statut:
epublish
Résumé
Patients with primary sclerosing cholangitis (PSC) frequently manifest features of autoimmune hepatitis (AIH). We sought to understand factors affecting expert management, with the goal of facilitating uniformity of care. A Survey Monkey questionnaire with four hypothetical cases suggesting a potential AIH/PSC variant was sent to hepatologists spanning global practices. Eighty responses from clinicians in 23 countries were obtained. Most of the respondents would request a liver biopsy, and stated that the cases presented could not be appropriately managed without a biopsy. Despite the fact that histology did not unequivocally support an AIH/PSC variant in three of the four cases, this diagnosis was reached by most of the respondents for all cases, except case 1, in which 49% were diagnosed with AIH/PSC. There was a wide variation of suggested medical treatment. For three cases, the most commonly chosen treatment options did not exceed 35%, indicating a lack management consensus. Most respondents would treat with ursodeoxycholic acid, despite current American Association for the Study of Liver Diseases guidelines, either alone or in combination with immunosuppression. European clinicians recommended ursodeoxycholic acid more frequently than their counterparts in North America (
Identifiants
pubmed: 32140656
doi: 10.1002/hep4.1467
pii: HEP41467
pmc: PMC7049681
doi:
Types de publication
Journal Article
Langues
eng
Pagination
399-408Informations de copyright
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
Références
J Hepatol. 2016 Oct;65(4):769-775
pubmed: 27238753
Hepatology. 2010 Feb;51(2):660-78
pubmed: 20101749
J Hepatol. 2009 Aug;51(2):237-67
pubmed: 19501929
Hepatology. 2017 Apr;65(4):1145-1155
pubmed: 27639088
J Hepatol. 2015 Oct;63(4):971-1004
pubmed: 26341719
Hepatology. 2009 Aug;50(2):528-37
pubmed: 19575454
Endoscopy. 2017 Jun;49(6):588-608
pubmed: 28420030
Hepatology. 2008 Jul;48(1):169-76
pubmed: 18537184
J Hepatol. 2011 Feb;54(2):374-85
pubmed: 21067838
Lancet. 2013 Nov 9;382(9904):1587-99
pubmed: 23810223
Scand J Gastroenterol. 2017 Dec;52(12):1407-1412
pubmed: 28851259
Neth J Med. 2007 May;65(5):167-77
pubmed: 17519512
World J Gastroenterol. 2008 Jun 28;14(24):3781-91
pubmed: 18609700
Gastroenterology. 2014 Apr;146(4):970-9; quiz e15-6
pubmed: 24389304
Aliment Pharmacol Ther. 2017 Mar;45(5):723-732
pubmed: 28004405
Int J Hepatol. 2015;2015:624596
pubmed: 26770833
Hepatology. 1996 Jun;23(6):1369-76
pubmed: 8675153